Navigation Links
BioMarin Announces FDA Approval for Kuvan
Date:12/13/2007

is no response, the drug dose may be increased to 20 mg/kg/day for up to a month. The dose may be adjusted within a range of 5 to 20 mg/kg/day in patients who respond to Kuvan. Kuvan is developed in partnership with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

Clinical Trial Study Results

The efficacy and safety of Kuvan were evaluated in four clinical studies in patients with PKU.

Study 1 -- A multicenter, open-label, uncontrolled clinical trial of 489 patients with PKU, ages 8 to 48 years (mean 22 years), who had baseline blood Phe levels greater than or equal to 450 umol/L and who were not on Phe- restricted diets. All patients received treatment with Kuvan 10 mg/kg/day for 8 days. Response to Kuvan treatment was defined as a greater than or equal to 30% decrease in blood Phe from baseline. Results: At Day 8, 96 patients (20%) were identified as responders.

Study 2 -- A multicenter, double-blind, placebo-controlled study of 88 patients with PKU who responded to Kuvan in Study 1. After a washout period from Study 1, patients were randomized equally to either Kuvan 10 mg/kg/day (N=41) or placebo (N=47) for 6 weeks. Efficacy was assessed by the mean change in blood Phe level from baseline to Week 6 in the Kuvan-treated group as compared to the mean change in the placebo group. Results: At baseline, the mean (+/-SD) blood Phe level was 843 (+/-300) umol/L in the Kuvan-treated group and 888 (+/-323) umol/L in the placebo group. At Week 6, the Kuvan-treated group had a mean (+/-SD) blood Phe level of 607 (+/-377) umol/L, and the placebo group had a mean blood Phe level of 891 (+/-348) umol/L. At Week 6, the Kuvan- and placebo-treated groups had mean changes in blood Phe level of -239 and 6 umol/L, respectively (mean percent changes of -29% (+/-32) and 3% (+/-33), respectively). The difference between the groups was statistically significant (p < 0.001). Change in blood Phe was noted in the Kuvan-treated group at Week 1 and su
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on the number of directly ... the third quarter ended September 30, 2014. Financial ... store sales increased by 8.1% compared to the third ... to RMB738.3 million (US$120.3 million) compared to RMB683.2 million in ...
(Date:11/24/2014)... , Nov. 24, 2014 Juno Therapeutics ... Therapy Designation to the company,s JCAR015 chimeric antigen ... treatment of relapsed or refractory B-cell acute lymphoblastic ... Memorial Sloan Kettering Cancer Center, where Phase 1 ... "The FDA,s action is important news for patients ...
(Date:11/24/2014)... -- Marta Rendon, MD, founder of the Rendon Center for Dermatology ... international key opinion leader in dermatology, was one of only ... to attend the international Aesthetic Experts Summit held ... at this gathering of over 600 physicians from 57 countries, ... experts from Asia and ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3
... The SEAS (Simvastatin and Ezetimibe in,Aortic Stenosis) study ... the combination of simvastatin (40 mg daily) and,ezetimibe ... Aortic stenosis (which involves partial blockage of ... common disease among older people in Western,populations. Left ...
... Must for Clinical Trials Management, WASHINGTON, ... Centers (AAHC) today launched a new Clinical ... center leaders,research administrators, and chief compliance officers ... for the,research enterprise, particularly to manage and ...
Cached Medicine Technology:Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4New AAHC Toolkit Available to Optimize Clinical Research Administration 2
(Date:11/26/2014)... The family foundation of Best Buy founder, ... Research Foundation (Meso Foundation), half of which will be ... Grant Program . The focus area of the Richard ... with organizations that can generate transformational results in education, ... founder and chairman emeritus of Best Buy Co., Inc., ...
(Date:11/26/2014)... 2014 Increasing incidence rate of ... regulations are expected to be prime pharmacovigilance market ... of acute and chronic ailments has resulted in ... development. Moreover, growing adverse drug reaction related hospitalization ... become the need of the hour in the ...
(Date:11/26/2014)... Francisco, CA (PRWEB) November 26, 2014 Gone ... hanker after cheap deals on Black Friday, which signifies the ... to clicking items into their shopping carts in the comfort ... crowds. , This Friday is going to be ... in a day, with an estimated $2.48 billion in revenue ...
(Date:11/26/2014)... Loffler Companies has been selected as a 2014 ... information and news publication for resellers of imaging technology, ... Loffler has earned this prestigious award and the seventh ... honor the best and the brightest in the imaging ... chosen for their innovative marketing and sales programs, community ...
(Date:11/26/2014)... 26, 2014 GI for Life announced ... reductions in prices of their popular nutritional supplements: ... D3 . Discounts of 40% will be offered ... for Life’s proprietary ColoVite supplement is a scientifically formulated ... colon health. One easy-to-take colon vitamin with ALL the ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:2014 Best Friday Deals Revealed by Top10InAction 2Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2
... unresolved issue as to whether interstitial brachytherapy has advantages compared ... nor do newer studies provide proof in this respect. This ... for Quality and Efficiency in Health Care (IQWiG) on 11 ... challenged the findings of research already completed in 2007. However, ...
... are at greater risk of an ectopic pregnancy because of ... provides evidence for the first time of how chlamydia can ... when an embryo implants outside the womb, in the Fallopian ... women who had had the sexually transmitted infection were more ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, Jan. ... through Rep. Gabrielle Giffords, brain on Saturday will likely cause ... how extensive that damage might be. However, doctors at ... congresswoman immediately after the shooting are already encouraged by her ...
... News) -- Intensive care unit (ICU) patients in single, private ... a new study finds. About 30 percent of patients ... serious illness and death, the study authors noted in background ... are associated with an increased length of stay of eight ...
... for nursing home residents with advanced dementia, a terminal ... avoidable and of limited clinical benefit, according to a ... affiliate of Harvard Medical School, published in the online ... on Jan. 10, 2011. , The study examined Medicare ...
... of scientists has created particles that closely mirror some of ... the way for the development of synthetic blood. The ... online Early Edition of the Proceedings of the National ... 2011 also could lead to more effective treatments for ...
Cached Medicine News:Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 2Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 3Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 4Health News:Wounded Congresswoman Responds to Simple Commands 2Health News:Wounded Congresswoman Responds to Simple Commands 3Health News:Wounded Congresswoman Responds to Simple Commands 4Health News:Private Rooms Cut Infection Risk in the ICU: Study 2Health News:Aggressive care raises Medicare costs in end-stage dementia 2Health News:Aggressive care raises Medicare costs in end-stage dementia 3Health News:UNC researchers inch closer to unlocking potential of synthetic blood 2Health News:UNC researchers inch closer to unlocking potential of synthetic blood 3
...
...
...
... plate system features an advanced design that ... Trinica system gives surgeons the flexibility to ... anatomy. Flexibility is built-in to every aspect ... the innovative Secure-Twist anti-migration system to the ...
Medicine Products: